US Stocks prediction

The figures revealed a disquieting tableau: Roivant’s revenues shyly nestled just below $2.2 billion, a far cry from the bountiful nearly $8 billion accrued in the same quarter the year prior-a veritable feast turned into a meager repast. Yet the sorrow did not halt at the revenue line; the company endured a descent into the abyss of a net loss, eclipsing $223 million-amounting to $0.33 per share-where once it had basked in the glow of a $95 million profit.

The SEC makes people like Griffin disclose their stock holdings every quarter. These disclosures, called 13F filings, are treated by many investors as though they’re sacred texts handed down from Mount Sinai. But let me tell you something about sacred texts-they rarely mention Charles Schwab or Keurig Dr Pepper. Here’s what Griffin’s hoarding these days, in case you were wondering:

Barron’s report on elongated wait times for the Model Y-now stretching from one to three weeks to a grotesque four to six-has been interpreted by some as evidence of renewed demand. Yet let us not forget: this is a company whose sales have hemorrhaged year-over-year in 2024, a season of Lent for EV enthusiasts. The tax credit’s impending expiration, that alms of $7,500, may yet drive a final stampede of buyers, as frantic as a horseman fleeing the Four Horsemen.

What does this sale mean for the alignment of insiders?
By the dawn of July 29, 2025, Andrew R. Harrison still held 18,930 shares-a tether, though loosened, to the fate of Alaska Air Group. Yet one wonders if such tethers are strong enough to hold when the winds of profit blow hard against them.

Now, if picking individual stocks feels as daunting as choosing which fork to use at a fancy dinner party, fear not! The S&P 500 is here to save your sanity-and possibly your portfolio. This index isn’t just any collection of companies; no sir, it’s like the Avengers of the stock market, minus the spandex. Only the crème de la crème make the cut, and when they falter (cue dramatic organ music), they’re shown the door faster than a bad vaudeville act.

But fear not! For all is not lost in the realm of mRNA. Whether Moderna can rebound and reclaim its former glory depends on three rather crucial developments, which we shall now examine with the enthusiasm of a man discovering a forgotten cigar case. Let us begin, if you’ll permit me, with the first.

Enter the trio of schemers: Fuzzy Panda, Muddy Waters, and Culper, who, with the solemnity of philosophers, have declared war on AppLovin’s Axon 2.0, its AI adtech marvel. “Treason!” they cry, alleging privacy violations and clandestine app installations. Yet, what have they gained but a chorus of yawns from the mighty Alphabet and Apple? One might say their plots are as effective as a screen door on a submarine.

A stock split, dear reader, is not unlike a magician’s sleight of hand. The numbers dance across the ledger-shares multiply, prices divide-but the essence remains unchanged. No gold is minted, no debt erased. And yet, the mere announcement of such an act can send ripples through the financial ether, awakening dormant passions and inflaming the hearts of those who believe they are witnessing something profound. But beware, for beneath the surface lies a system as absurd as it is unyielding-a system where perception often trumps reality, and where even the most rational among us bow to its whims.

As of mid-2025, Alphabet’s portfolio-worth over $2.1 billion spread across 36 companies-reveals a curious alchemy of ambition and divestment. One holding has ascended like Icarus to the sunlit zenith of its favor, while another has been cast off like a moth-eaten cloak. Let us then embark on this literary exploration of capital’s caprices, where moonshots are launched and erstwhile darlings discarded.

Artificial intelligence (AI) stocks were having a moment last week-think Beyoncé-level buzz-but Supermicro’s valuation decided to pull a 2016 Fyre Festival. After releasing its Q4 results, the company’s sales and earnings fell short of market expectations, even though it offered forward guidance that sounded suspiciously like a pep talk from your boss before layoffs.